Skip to main content
. 2021 Jun 17;22(1):77–86. doi: 10.17305/bjbms.2021.5691

FIGURE 5.

FIGURE 5

FAM225B up-regulates CCND2 expression through inhibiting miR-613. (A,B) Relative mRNA (A) and protein (B) expression of CCNB2 in CNE-2 and SUNE-1 cells transfected with si-NC or si-FAM225B and miRNA negative control or miR-613 inhibitor. (C) Relative CCND2 expression of sh-FAM225B and sh-NC group in xenograft tissues. (D) Predicted binding sites of miR-613 in CCND2 3'UTR using TargetScan. (E, F) Relative luciferase activity in CNE-2 (E) and SUNE-1 (F) cells transfected with CCND2-wt or CCND2-mut reporter vector with miR-613 mimics or miRNA negative. (G) Relative expression level of CCND2 in NPC tissues and adjacent normal tissues determined using qRT-PCR. (H) Pearson correlation analysis of CCDN2 and FAM225B in 56 NPC tissues. **p < 0.01. CCND2: Cyclin D2; FAM225B: Family with sequence similarity 225 member B; miR: MicroRNA; miRNA-NC: MicroRNA negative control; miR-613-in: microRNA-613 inhibitor; mut: Mutant; NPC: Nasopharyngeal carcinoma; sh-FAM225B: Short hairpin RNA targeting FAM225B; sh-NC: Short hairpin RNA negative control; si-FAM225B: Small interfering RNA targeting FAM225B; si-NC: Small interfering RNA negative control; wt: Wild type; qRT-PCR: Quantitative reverse transcription polymerase chain reaction.